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The cancer stem cell (CSC) hypothesis proposes that CSCs are responsible for metastasis and disease
recurrence. Therefore, targeting CSCs has the potential to significantly improve outcomes for cancer
patients. The OCT4 transcription factor gene is a master gene that plays a key role in the self-renewal
and pluripotency of stem cells. In this study, we introduced an OCT4 reporting vector into 4T1 mouse
breast cancer cells and sorted OCT4 high and OCT4 low cell populations. We then determined whether
OCT4 expression is associated with maintenance and expansion of CSCs. We found that OCT4
high 4T1
cells have an increased ability to form tumorsphere and a high expression of stem cell markers such as
Sca-1, CD133, CD34, and ALDH1, when compared with OCT4
low 4T1 cells. In addition, OCT4
high 4T1 cells
have greater tumorigenic potential in vivo. These findings suggest that OCT4 expression may be a useful
target for stem cell-specific cancer therapy.
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The cancer stem cell (CSC) hypothesis proposes that CSCs,
which constitute a small population of cells within a tumor,
are able to self-renew and to give rise to diverse cellular
progeny. Indeed, CSCs may be responsible for the escape
of tumors from conventional therapies, resulting in residual
CSCs that can lead to disease recurrence and metastasis [1-
3]. Therefore, CSC-specific therapies might prevent cancer
relapse and completely destroy cancer at its root.
The OCT4 (also known as POU5F1) transcription factor
gene is known as a master pluripotency gene [4,5]. Kim and
colleagues showed that OCT4 alone is sufficient to directly
reprogram adult mouse neural stem cells to pluripotent stem
(iPS) cells [6]. Clinical studies have shown that tumors with
intense expression of the OCT4 stem cell marker are
associated with further disease progression, greater metastasis,
and shorter cancer-related survival compared with tumors
with moderate and low OCT4 expression [7]. Furthermore,
OCT4 is reported to be a core regulator of stem cell self-
renewal and differentiation, and was recently validated as
a CSC target [8]. Based on these findings, our study attempts
to identify the CSC population characterized by the OCT4
phenotype among 4T1 mouse breast cancer cells. To this
end, we stably infected 4T1 cells with a retroviral particle
which contains the mouse OCT4 promoter and drives
expression of red fluorescent protein (RFP). The goal was
to determine whether targeting of OCT4 expression is a feasible
strategy for stem specific cancer therapy in a rigorously defined
mouse 4T1 breast tumor model.
Materials and Methods
Cell culture
Mouse breast cancer cell lines (67NR and 4T1) and human
breast cancer cell lines (MCF-7, T-47D, MDA-MB-231, and
Hs578T) were cultured in DMEM (Invitrogen, Grand Island,
NY, USA) containing 10% FBS and 1% penicillin /streptomycin
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(Invitrogen), as previously described [9-11]. The 4T1-Luc-
OCT4 cell line was established by infection of 4T1-Luc cells
(Caliper Life Sciences, Hopkinton, MA, USA) with a mouse
OCT4-pRFPZeo packaged virus particle (System Biosciences,
Mountain View, CA, USA) according to the manufacturer’s
protocol. Stable transfectants were selected by incubation with
zeocin (300 mg/mL, Invitrogen), and OCT4 expression was
determined using a fluorescent microscope (Carl Zeiss,
Thornwood, NY, USA).
Flow cytometry
FACS analysis and sorting were performed using a FACS
Calibur and FACSAria (Becton Dickinson, Franklin Lakes, NJ,
USA), respectively. FACS data were analyzed using Flowjo
software (Tree Star, Ashland, OR, USA). The Aldefluor kit
(Stem Cell Technologies, Vancouver, Canada) was used to
isolate a population with high aldehyde dehydrogenase
(ALDH) enzymatic activity, according to the manufacturer’s
instructions. The following antibody was used: OCT4 (Abcam,
Cambridge, MA, USA). An APC-conjugated rabbit IgG
antibody (Molecular Probes, Eugene, OR, USA) was used
for visualization.
Tumorsphere culture
Tumor sphere culturing was performed as previously
described [12,13]. After 7 to 10 days of culturing, wells were
examined under an inverted microscope at x50 magnification,
and the number and diameter of spheres was determined
for independent fields per well using the Image-Pro Plus
program (Media Cybernetics, Bethesda, MD, USA).
In vivo limiting dilution assay
All animals were maintained according to IACUC approved
protocols of the Lee Gil Ya Cancer and Diabetes Institute,
Korea. For titration experiments, the left and right thoracic
(#2) mammary fat pads (m.f.p.) of anesthetized 7-week-old
female Balb/c mice (Orient Charles River Technology, Seoul,
Korea) were surgically exposed and sorted 4T1 cells were
inoculated into m.f.p. in a 50 mL volume (n=3/group).
Tumor incidence was assessed via in vivo bioluminescence
measurement using an IVIS Imaging System (Caliper Life
Sciences). For luciferase detection, 150 mg/mL D-luciferin
(Caliper Life Sciences) in PBS was injected intraperitoneally
before imaging. Photometric measurement of tumors was
done by Living Image software (V. 3.1.0, Caliper Life Sciences).
Quantitative reverse-transcription-polymerase chain
reaction (RTQ-PCR)
RTQ-PCR for quantification of cDNA was performed using
SYBR green PCR master mix (Applied Biosystems, Foster City,
CA, USA) and the ABI 7300 real-time PCR system according
to the manufacturer’s instructions. The quantitative RT-PCR
was done in triplicate. Mouse mRNA levels were normalized
with mouse hypoxanthine-guanine phosphoribosyltransferase
(HPRT). The primer sets used in this study were as follows:
OCT4: 5'-GCATTCAAACTGAGGCACCA-3' (forward) and 5'-
AGCTTCTTTCCCCATCCCA-3' (reverse); Sca-1: 5'-TCA GTC
CTC CTG CAG ACC TT-3' (forward), 5'-ACTCCCACCTTGGA
GCTTCT-3' (reverse); ALDH1: 5'-GCTAGCTACAATGGAGG
CACTCA-3' (forward), 5'-GCA GCCTCCTAAATCCGACA-3'
(reverse); CD133: 5'-CACTTGATGCCACTGCCAAA-3' (forward),
5'-TGACACTGAACGTAATGCCCAT (reverse); CD34: 5'-
AAAGGCCAATGTGACCCGA-3' (forward), 5'-TGCCACTTTC
CTGCATACCAC-3' (reverse); CD90: 5'-TCCAAGCCCTGGAC
TTCA TTT C-3' (forward), 5’-CCGTTT CTCCCCATGTTCT
GAG-3' (reverse); HPRT: 5'-GCCTAAGATGAGCGCAA GTTG-
3' (forward), 5'-TACTAGGCAGATGGCCACAGG-3' (reverse).
Statistical analysis
All experiments were done 3 or more times, and the results
are expressed as mean±SD. Statistical analyses of these data
were done using an unpaired Student’s t-test for parametric




pos  CSC  population  has  a  high  OCT4
expression
The expression of ALDH as assessed by the Aldefluor assay
has been recognized as a marker for malignant stem cells
in breast cancers [14]. To evaluate OCT4 expression in the
CSC population characterized by high ALDH activity, we
compared the expression of OCT4 in ALDH
neg and ALDH
pos
cell population sorted from 4T1 cells. RTQ-PCR analysis
showed a significant increase (~3.3-fold) of OCT4 mRNA
expression in ALDH
pos 4T1 cells (Figure 1A). To confirm the
correlation between ALDH activity and OCT4 expression,
we examined OCT4 expression in ALDH
neg and ALDH
pos
cell population from various mouse and human breast cancer
cell lines. FACS analysis showed that expression of OCT4
significantly increased (3.3- to 9.5-fold) in ALDH
pos cell
population compared with ALDH
neg cell population of breast
cancer cell lines (Figure 1B).
OCT4
high 4T1 cell population has high tumorsphere
forming ability
It has been reported that cancer stem-cell like cells canThe role of OCT4 expression in 4T1 breast cancer model 149
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be cultured in vitro to test stem cell properties such as self-
renewal in serum-free medium with bFGF and EGF [12].
To determine whether 4T1 cells showing OCT4
high have high
sphere-forming ability, we introduced an OCT4-RFP vector
into 4T1-Luc cells (Figure 1A), sorted 4T1-Luc cells into
OCT4
low and OCT4
high cell population, and plated the freshly
isolated cell populations under tumorsphere forming culture
conditions (Figure 2A). Only the OCT4
high cell population
grew into typical spheres and they showed much larger and




high 4T1 cell population has more tumorigenic
potential in vivo in immune-competent mice
To investigate the in vivo tumorigenic ability of OCT4
high
cell population, we injected sorted cells into the mammary
glands of mice. As shown in Table 1, OCT4
high 4T1-Luc cells
gave rise to tumors in five of six inoculations (83.3%) with
as few as 100 cells. At the same injection dose (100 cells),
OCT4
low 4T1-Luc cells gave rise to tumors in 16.6% of trials
(one of six inoculations). The OCT4
high cell population showed
~5-fold enrichment compared with the OCT4
low cell
population. At 100-cell inoculation, in vivo imaging showed
Figure 1. ALDH
pos 4T1 cells show a large increase in OCT4 expression in breast cancer cells. (A) RTQ-PCR analysis of OCT4 in
ALDH
neg and ALDH
pos 4T1 cells. Left panel, the contour plot shows the percentage of ALDH activity in 4T1 cells. (B) Flow cytometry
profiles of OCT4 expression on ALDH
neg or ALDH
pos cell population derived from breast cancer cell lines (67NR, 4T1, MCF-7, T-
47D, MDA-MB-231, and Hs578T). Values are mean±SD. *P<0.05 is a statistically significant difference.150 Ran-Ju Kim and Jeong-Seok Nam
Lab Anim Res | June, 2011 | Vol. 27, No. 2
an increase (~2-fold) in bioluminescence in the primary tumor
generated by OCT4
high 4T1-Luc cells, compared with OCT4
low
4T1-Luc cells (Figure 3). These results demonstrate that the
OCT4
high cell population has more tumorigenic potential in
vivo in an immune competent microenvironment.
The OCT4
high 4T1 cell population has high expression
of stem cell markers
To further characterize the OCT4
high cell population, we
compared expression profiles of stem cell marker genes [13-
18] in OCT4
low and OCT4
high cell population sorted from
4T1-Luc cells. RTQ-PCR analysis showed significant increases
(~2-fold to 3-fold) for Sca-1, CD133, CD34 and ALDH1
expression but no significant change in CD90 expression in
the OCT4
high cell population over the OCT4
low cell population
(Figure 4). Taken together, these results show that the expression




The  OCT4 gene, a member of the POU family of
transcription factors, was shown to be expressed in stem cells
[19,20]. In this study, we applied OCT4 positive cell analysis
and sorting to cause enrichment in putative CSCs in the 4T1
mouse model. The 4T1 breast cancer model is widely
considered to be one of the best syngeneic xenograft mouse
Figure 2. An OCT4
high cell population isolated from 4T1-Luc cells has a high efficiency of tumorsphere formation in vitro. (A) The
level of red fluorescence was determined in mOCT4-RFP infected 4T1-Luc cells using a fluorescence microscope. (B) The ability of
OCT4
low and OCT4
high 4T1-Luc cells cultured in low attachment dishes to form spheres was determined as described in Materials
and Methods. Values are mean±SD. *P<0.05 is a statistically significant difference.
Table 1. Tumor-initiating ability of the OCT4
high cell population in
the 4T1 syngeneic mouse model
Cell type






low 3/6 2/6 1/6
OCT4
high 5/6 5/6 5/6
aThese cells injected into mammary fat pad of Balb/c mice at
varying initial cell counts.The role of OCT4 expression in 4T1 breast cancer model 151
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models for the study of human cancer progression [21,22].
To our knowledge, this is the first report that OCT4 may
be a good marker for CSC characterization in an immune-
competent syngeneic tumor microenvironment. This
conclusion was supported by the following findings. First,
the size of the OCT4
high cell population isolated from 4T1
cells was positively correlated with tumorigenicity in immune-
competent mice compared with the OCT4
low cell population.
Second, CSCs expressing OCT4 displayed high tumorsphere
forming ability in vitro. Third, the OCT4
high cell population
had high expression of stem cell markers compared with
the OCT4
low cell population.
Self-renewal and pluripotency are central features in the
definition of stem cell populations, and OCT4 is a key regulator
in these processes [19, 23]. Further, the expression of OCT4
has been shown in human breast cancer stem-like cells,
implicating its involvement in self-renewal and tumorigenesis
[24]. Recently, Hu and colleagues suggested that a reduction
in OCT4 expression in lung CSCs induces apoptosis and the
inhibition of tumor growth partly through the OCT4/Tcl1/
Akt1 pathway [8]. In addition, OCT4 was recently reported
to play a critical role in survival/apoptosis of embryonic stem
cells via stat3/survivin [25]. However, the detailed molecular
roles of OCT4 in cancer stemness have not yet been fully
elucidated. Therefore, additional studies are necessary to look
into downstream molecular mechanisms by which OCT4
regulates the maintenance and expansion of CSCs.
In summary, the present work suggests that high expression
of OCT4 enhances stem cell properties in a mouse model
of breast cancer. Thus, OCT4 may represent a target molecule
for the treatment of advanced cancer.
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